DIABETES and DIABETIC FOOT ULCER PROGRAM

Diabetes Mellitus

Diabetes Mellitus, more commonly known as just diabetes is one of the most common chronic diseases in the world and is due to an irregular high level of sugar (glucose) in the blood stream as a result of either the pancreas not producing adequate amount of insulin or the cells no longer respond to the insulin produced. Insulin is an important hormone that is required by the cells to remove sugar and to use it for energy or to store for future use.

Inadequate management of sugar levels in the blood stream leads to serious disorders including kidney (renal) failure, heart problems, blindness and stroke.

Diabetes Mellitus program offered in Cuba includes the following:

  • 10 Nights of hospitalization. (Hospitalization will include accommodation in a private room, nursing care and medical assistance, evaluation and preparation of medical history, as well as three course meals and scheduled diagnostic tests)
  • Consultation with an endocrinologist
  • Consultation with ophthalmologist
  • Electrocardiogram test
  • Glycated [Glycosylated] Haemoglobin (HbA1c) test
  • Chest X ray
  • Upper abdominal ultrasound CBC
  • Uric acid test
  • Creatinine test
  • Glycemia test (6)
  • Full lipid panel
  • Urea test
  • Cyturia test
  • Microalbuminuria test
  • Insulinemia test
  • Motor and sensory test
  • Nerve conduction of the 4 members

Please note that each treatment program is tailored to each individual case depending on the severity of the condition and the overall health of the patient

Diabetic Foot Ulcer – Heberprot-P

Heberprot-P is a drug developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Cuba for the treatment of severe diabetic foot ulcer which has epidermal growth factor (EGF) as it’s main ingredient and is parenteral administered (intra-lesional injections directly in the wound). About 160,000 diabetic foot ulcer patient have been treated with Heberprot-P with success reducing the the risk of amputation by %75.

Diabetic patients have a decreased amount of growth factor concentrations, mainly epidermal growth factor receptor (EGF). EGF is an important growth factor that promote cell growth and cell proliferation by binding to the epidermal growth factor receptors (EGFR). A reduced amount of EGF impairs wound healing to such extremes as to may require amputation. Heberprot-P encourages healing in a progressive and sustained manner.

Heberprot-P is given for treatment for patient suffering chronic nonhealing wounds with poor prognosis and those not responding to extensive conventional methods of treatment.

Treatment for Diabetic Foot Ulcer with Heberprot-P includes:

  • Internal medicine specialist care
  • Hemoglobin, hematocrit, erythrocyte sedimentation rate laboratory tests
  • Microbiology – Microbiological swab with antibiogram to determine sensitivity of an isolated bacterial strain to different antibiotics
  • Chest X ray
  • Radiograph of foot
  • Full abdominal diagnostic ultrasound
  • Electrocardiogram
  • Angiology tests – Arterial hemodynamic study blood flow or the circulation.

This is a 4 week hospitalized program. Please note that the classification of the lesion and the patient reaction to Heberprot-P treatment may be extended up to 8 weeks.